Barclays Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Investment analysts at Barclays initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued on Friday, MarketBeat reports. The firm set an “overweight” rating and a $923.00 price target on the biopharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 21.48% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Oppenheimer reissued an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $759.82 on Friday. The company’s fifty day simple moving average is $770.81 and its two-hundred day simple moving average is $688.75. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market cap of $80.33 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 2.04 and a beta of 0.41. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the business posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. increased its stake in Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after purchasing an additional 6,073 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares in the last quarter. PGGM Investments grew its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after buying an additional 8,187 shares during the last quarter. Rakuten Investment Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $33,121,000. Finally, Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $64,677,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.